|
|
Blood, 1 May 2004, Vol. 103, No. 9, pp. 3300-3302.
Prepublished online as a Blood First Edition Paper on December 24, 2003; DOI 10.1182/blood-2003-11-3852.

Submitted November 20, 2003
Accepted December 14, 2003
Erythropoietin gene therapy leads to autoimmune anemia in macaques
Guangping Gao, Corinna Lebherz, Daniel J Weiner, Rebecca Grant, Roberto Calcedo, Adam Bagg, Yi Zhang, and James M Wilson*
Gene Therapy Program, University of Pennsylvania, Philadelphia, PA, USA; The Wistar Institute, Philadelphia, PA, USA
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA
Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA
* Corresponding author; email: wilsonjm{at}mail.med.upenn.edu.
Gene therapy is being considered for the delivery of therapeutic proteins. We evaluated the delivery of the hormone erythropoietin into cynomolgus macaques via intramuscularly administered adeno-associated virus (AAV) vectors. As expected, the animals developed supraphysiologic levels of Epo and polycythemia. However, a severe anemia ensued in some animals due to an autoimmune response to endogenous and transgene derived Epo. This is the first example of gene therapy leading to inadvertent autoimmunity in primates.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
Inadvertent autoimmunity in EPO gene transfer
- Els Verhoeyen and François-Loïc Cosset
Blood 2004 103: 3248-3249.
[Full Text]
[PDF]
-
Autoimmune anemia in macaques following erythropoietin gene therapy
- Pierre Chenuaud, Thibaut Larcher, Joseph E. Rabinowitz, Nathalie Provost, Yan Cherel, Nicole Casadevall, Richard J. Samulski, and Philippe Moullier
Blood 2004 103: 3303-3304.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
Y. Lu and S. Song
Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors
PNAS,
October 6, 2009;
106(40):
17158 - 17162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-M. Lai, M. J. Estcourt, M. Wikstrom, R. P. Himbeck, N. L. Barnett, M. Brankov, L. B. G. Tee, S. A. Dunlop, M. A. Degli-Esposti, and E. P. Rakoczy
rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector
Invest. Ophthalmol. Vis. Sci.,
September 1, 2009;
50(9):
4279 - 4287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hsieh, N. S. Linde, A. Wynter, M. Metzger, C. Wong, I. Langsetmo, A. Lin, R. Smith, G. P. Rodgers, R. E. Donahue, et al.
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques
Blood,
September 15, 2007;
110(6):
2140 - 2147.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Eliopoulos, R. F. Gagnon, M. Francois, and J. Galipeau
Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure
J. Am. Soc. Nephrol.,
June 1, 2006;
17(6):
1576 - 1584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Lippin, M. Dranitzki-Elhalel, E. Brill-Almon, C. Mei-Zahav, S. Mizrachi, Y. Liberman, A. Iaina, E. Kaplan, E. Podjarny, E. Zeira, et al.
Human erythropoietin gene therapy for patients with chronic renal failure
Blood,
October 1, 2005;
106(7):
2280 - 2286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. R. Arruda, H. H. Stedman, T. C. Nichols, M. E. Haskins, M. Nicholson, R. W. Herzog, L. B. Couto, and K. A. High
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
Blood,
May 1, 2005;
105(9):
3458 - 3464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda
Factor IX variants improve gene therapy efficacy for hemophilia B
Blood,
March 15, 2005;
105(6):
2316 - 2323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. M. Rivera, G.-p. Gao, R. L. Grant, M. A. Schnell, P. W. Zoltick, L. W. Rozamus, T. Clackson, and J. M. Wilson
Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer
Blood,
February 15, 2005;
105(4):
1424 - 1430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Johnson, B. C. Schnepp, M. J. Connell, D. Rohne, S. Robinson, G. R. Krivulka, C. I. Lord, R. Zinn, D. C. Montefiori, N. L. Letvin, et al.
Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques
J. Virol.,
January 15, 2005;
79(2):
955 - 965.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Chenuaud, T. Larcher, J. E. Rabinowitz, N. Provost, Y. Cherel, N. Casadevall, R. J. Samulski, and P. Moullier
Autoimmune anemia in macaques following erythropoietin gene therapy
Blood,
May 1, 2004;
103(9):
3303 - 3304.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|